Cytology frequently has some role in preoperatively distinguishing pancreatic mucus-producing neoplasia (intraductal papillary mucinous neoplasms [IPMNs] and mucinous cystic neoplasms [MCNs] Until recently, the discussion of pancreatic cystic neoplasia would have been considered rather academic. It was thought to be rare and had been classified disparately within a number of different systems. The discussion of the cytologic features of such lesions was then abstruse, confined to case reports and short paragraphs in comprehensive cytology textbooks.
Until recently, the discussion of pancreatic cystic neoplasia would have been considered rather academic. It was thought to be rare and had been classified disparately within a number of different systems. The discussion of the cytologic features of such lesions was then abstruse, confined to case reports and short paragraphs in comprehensive cytology textbooks.
In the past 20 years, things have changed. Not only has diagnostic imaging become more sensitive, with computed tomography and magnetic resonance imaging now able to detect lesions smaller than a centimeter, but it has come to be more routinely used for less and less specific complaints. It is now known that pancreatic cysts are quite common and that many are neoplastic. 1, 2 Pancreatic surgery has also become more common. Although the surgical procedures have not changed drastically, technical expertise has improved, especially at larger centers specializing in pancreatic surgery, and mortality and morbidity rates have improved considerably. 3, 4 The pathologic classification of pancreatic pathology has followed suit, culminating in the somewhat recent publication of the World Health Organization text, Pathology and Genetics of Tumours of the Digestive System. 5 Led by experts at a number of institutions, a great number of articles have been published in the past 20 years describing and clarifying the various pathologic entities of the pancreas. The use of immunohistochemical and molecular methods has further increased our understanding of invasive and preinvasive disease.
Although pancreatic surgery has improved, the preoperative diagnosis of disease remains challenging. Radiographic findings positively predict neoplasia, per se, accurately with most larger and solid-appearing lesions. With surgical candidates, the definitive classification of such lesions is not always necessary before surgery and can be performed with the resected specimen. Most solid masses remain unresectable, however, and, because different lesions may require different chemotherapeutic therapies, cytologic examination is used to classify them. While radiology has improved in predicting cystic pancreatic neoplasia, the positive and negative predictive values of its interpretations remain insufficient.
Coincident with the increased need for the diagnosis of pancreatic mass and cystic lesions has been the development and dissemination of endoscopic ultrasound (EUS). 6 Not only does it allow for the assessment of the pancreatic lesion and possible sites of metastasis, such as peripancreatic and celiac lymph nodes and the liver, it also allows for the sampling of the pancreatic lesion by fine-needle aspiration (FNA).
Thus, there have developed the increased need for the preoperative diagnosis of pancreatic lesions and a better means for collection of cytologic samples. A good number of articles have been published during the past several years specifically discussing the cytologic diagnosis of pancreatic cystic lesions. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Most have been retrospective reviews of single diagnostic entities and have attempted to define the cytologic features of these entities along with the findings of various ancillary tests, most commonly cyst fluid analyses. 9 Our study was designed to investigate the use of the various cytologic features that have been touted for the diagnosis of pancreatic cystic mucus-producing neoplasia (ie, intraductal papillary mucinous neoplasms [IPMNs] and mucinous cystic neoplasms [MCNs] ) and the distinction of these lesions from other pancreatic cysts.
Materials and Methods
The surgical pathology files of one institution (University of Virginia, Charlottesville) were reviewed for all resected or biopsied pancreata received during approximately 15 years (January 1, 1991-October 15, 2006) . The slides of all cases not diagnosed as conventional pancreatic ductal adenocarcinoma were reviewed, and all neoplasia was classified according to the most recent World Health Organization classification system for pancreatic neoplasia. 5 IPMNs were graded and classified according to the most recent consensus statement, and MCNs were classified using similar cytologic criteria. 21 Briefly, grade 1 tumors had basally located nuclei with minimal cytologic atypia. Grade 2 tumors had some nuclear stratification with moderate cytologic atypia. Grade 3 tumors had cytologic atypia similar to that seen with invasive tumors. IPMNs were then subtyped as gastric foveolar, pancreatobiliary, or intestinal. An IPMN was considered the foveolar type when it was low grade, with basally located round to oval nuclei and abundant, lightly eosinophilic apical cytoplasm. An IPMN was considered the intestinal type when the neoplastic change most closely resembled colonic adenomatous change. In such cases, the nuclei showed moderate cytologic atypia and were stratified, oval, and hyperchromatic. The pancreatobiliary type resembled conventional pancreatic intraepithelial neoplasia.
The cytology files were then searched for any cytologic specimens corresponding to resected or biopsied cystic pancreatic lesions (eg, IPMNs, MCNs). Seven cytologic samples procured at another institution (Hennepin County Medical Center, Minneapolis, MN) from pancreatic cystic lesions with follow-up surgical resections were also evaluated.
All cytologic samples were reevaluated for the presence of lesional extracellular and cellular material. Lesional extracellular material was defined as previously and was characterized cytologically as atypical amorphous mucoid material that appeared more abundant and/or thicker than the extracellular mucus that may be seen with the gastrointestinal contaminant sometimes sampled by EUS-guided FNA. 20 A lesional cellular component was defined as any cellular component that was not believed to be gastrointestinal contaminant or normal pancreatic parenchyma ❚Image 1❚. The cellular component was further classified when possible. Cytologic results were then compared with final surgical diagnoses.
Results
We reviewed 52 cytologic samples from 40 histologically diagnosed pancreatic cystic lesions. The histologic diagnoses and cytologic findings are shown in ❚Table 1❚.
❚ ❚Image 1❚ ❚ Typical gastrointestinal contaminant extracellular and cellular material gathered by endoscopic-ultrasound-guided fine-needle aspiration.
Of note, lesional extracellular material was identified in 32 of 38 cytologic samples from cystic pancreatic mucus-producing neoplasms ( cases and lesional cellular material in 9 of 14 cases. Samples from IPMNs with an intestinal phenotype were found to have lesional extracellular material in 10 of 10 cases and lesional cellular material in 4 of 10 cases, whereas those from IPMNs with a foveolar or pancreatobiliary phenotype were found to have lesional extracellular material in 18 of 21 cases and lesional cellular material in 13 of 21 cases. The lesional cellular components were obviously glandular in all cases and ranged from sheets of mildly atypical epithelial cells, seen in the aspirates from the lower grade tumors, to single cells and small clusters of malignant-appearing glandular cells. Although higher grade and invasive lesions were more likely to have lesional cellular material identified within their corresponding cytologic specimens, the difference was not statistically significant (P > .05).
Lesional extracellular material was seen in 3 of 14 samples of other pancreatic cysts, and lesional cellular material was seen in 6 of 14 cases ❚Image 4❚. The lesional extracellular material was identified in aspirates from a case of metastatic colon cancer, a cystic pancreatic endocrine tumor, and a pancreatic lymphoepithelial cyst. Of note, an air-dried rapid Romanowsky-stained smear was not made for the cystic pancreatic endocrine tumor. Nevertheless, the lesional cellular material seen in that case was not glandular in appearance and had cytologic features most consistent with an endocrine tumor (ie, highly cellular aspirate with numerous loose clusters of cells and single cells; cells had a monomorphic plasmacytoid appearance with granular chromatin) (Image 4). The metastatic colon cancer could be diagnosed as such only because of the patient's history of colon cancer. The cytologic features were indistinguishable from a high-grade IPMN with an intestinal phenotype (Image 4). Finally, although the lesional extracellular material seen in the aspirate of the pancreatic lymphoepithelial cyst appeared somewhat different from that of the aspirates from the pancreatic cystic mucus-producing neoplasms, it could not the identified as something distinctly different. (In retrospect, it is believed to be keratinous debris, although definitive squamous cells were not present.) The atypical lesional cells seen with that case were glandular and, in retrospect, are believed to represent contaminant gastric epithelium. The remaining cases that showed lesional cellular material in the aspirate included 2 more cases of pancreatic lymphoepithelial cysts and an additional cystic pancreatic endocrine tumor. In these cases, the lesional cellular components were prospectively diagnostic of the patients' follow-up diseases.
Conclusions
A little more than 35,000 people in the United States will die of pancreatic cancer during the next year-roughly the same number that will be diagnosed with pancreatic cancer. 22 This is due to a number of issues but results primarily because most pancreatic cancers are pancreatic ductal adenocarcinomas and, when these cancers are detected, they are almost always incurable. To decrease the number of deaths due to the disease, these cancers need to be detected earlier, allowing for cure through surgical management, or other effective therapeutic modalities have to be developed.
It is currently difficult to envision how pancreatic cancer will be detected earlier than it already is. Mass radiographic screening would be prohibitively expensive, and familial or even risk-related selected screening would detect too few cases (familial) or also be too expensive because our current understanding of the risks for the development of pancreatic cancer remains limited to common habits (eg, smoking) that carry only little relative risk for the development of the disease. Furthermore, the benefit of detecting small pancreatic cancers would likely be limited because even small lesions (<2 cm in greatest dimension and confined to the pancreas, ie, T1) are, for the most part, deadly. 23 Finally, it is unclear how many false-positive radiographic diagnoses would result if mass screening were performed and smaller, nonsymptomatic lesions were found. Thus, it may be best to detect preinvasive disease, ie, pancreatic intraepithelial neoplasia. The difficulty is again 2-fold. For one thing, lower grade intraepithelial lesions are common, and autopsy studies or studies of pancreata resected for disease other than pancreatic ductal adenocarcinoma have shown that most older people have intraepithelial lesions. [24] [25] [26] [27] [28] Pancreatic intraepithelial neoplasia is also, for the most part, undetectable, and patients are generally without symptoms or radiographically detectable changes. The exceptions to this are the intraepithelial lesions that lead to cystic dilatation, ie, IPMNs and MCNs.
Pancreatic cysts are not as uncommon as once believed, and the touted dogma that the vast majority are pseudocysts may not be as true as it once seemed. Regardless of how common pseudocysts are, samples from neoplastic cysts now make up a high percentage of the aspirates that we see at our institutions as radiologists and endoscopists have come to recognize many of the lesions clinically and by imaging. In our own unpublished data, samples from neoplastic pancreatic cysts seem to represent nearly one third of our pancreatic cyst samples. Despite the numerous articles about the cytologic features of pancreatic cysts, the role of cytopathologists in the diagnosis and treatment of these lesions remains somewhat unclear. Currently, it is recommended that IPMNs larger than 3 cm or with main duct dilatation be resected. It is also recommended that any MCN be resected. Aside from assisting with the actual classification of the lesions, cytologic examination can lead to the resection of smaller IPMNs if atypical cells are identified, and it has been shown in a number of studies that atypical glandular cells predict, not surprisingly, in situ or invasive malignancy. 29 But what exactly is the role of cytologic examination in the classification of these lesions? The identification of atypical mucus and/or atypical glandular cells by cytologic examination likely supersedes a favored radiologic impression or chemistry findings when they disagree. With only one of our cases did we have a true false-positive in which we saw lesional extracellular and cellular components (albeit erroneously interpreted as such) that made us favor a diagnosis of cystic mucinous neoplasia. (In all other cases with lesional extracellular material, we were able to identify a lesional cellular component that was diagnostic of a different pancreatic lesion.) That case was found at resection to be a lymphoepithelial cyst and had been favored by radiology to be a large side-branch IPMN (because it was in a man) and by chemistry had a markedly high carcinoembryonic antigen concentration. The role of cytologic examination in that case only could have been to overturn the radiographic and chemical findings, which, in the absence of definitive squamous cells, we were wont to do.
We also believe that if cytologic findings favor an alternative diagnosis, such a diagnosis should be favored over the radiographic or chemical findings, especially with cystic pancreatic endocrine tumors or solid pseudopapillary tumors with which the cytologic features are generally specific enough to preclude other diagnoses. The prediction of other nonneoplastic disease is trickier business, however. Does the identification of material that appears to be from a pseudocyst preclude a clinical impression of neoplasia when pseudocysts can develop secondary to other neoplasms? Does the identification of mature, benign-appearing squamous cells positively predict a lymphoepithelial cyst at resection when squamous cells can inadvertently be "sampled" by the echoendoscope as it passes though the mouth and esophagus?
Nonspecific negative cytologic findings certainly do not preclude cystic-appearing mucinous neoplasia or even malignant mucinous neoplasia (in situ or invasive), as can be seen with our cases. Currently, it is somewhat difficult to estimate what percentage of the false-negative cases (ie, cases found to be cysticappearing mucinous neoplasia at resection after having been deemed to be negative and nonspecific by cytologic examination) are due to sampling, especially because how sampling materials were split is rarely recorded in studies. Our own experience with truly split samples suggests that both may have a role because carcinoembryonic antigen concentrations can vary greatly between these cases.
Despite the many pancreatic cyst cytologic studies, the true positive and negative predictive values remain unknown because, for a variety of reasons, most pancreatic cysts do not get resected. Furthermore, the pancreatic cysts that do get resected are resected, in general, because they are suspected to be IPMNs or MCNs, especially when these tumors are believed to have a high chance of harboring in situ or invasive malignancy (a judgment in which cytologic examination has some role). Thus, selection bias may cause most cytologic studies that use histologic findings as the "gold standard" to have artificially high sensitivities. For this reason, we are loath to calculate these statistics with our series that has used resected pancreata as the gold standard and as a criterion for inclusion in the study.
Despite the din of the lofty calls for evidence-based medicine, much of our practice remains an art. Our understanding of tests and how they function develops with our use of the test, while we try to give each prospective patient the best service possible. This holds true with the use of cytologic examination for the preoperative distinction of pancreatic cysts. Currently, with the assessment of extracellular and cellular material, we are able to identify most neoplastic pancreatic mucus-producing cysts (that are resected).
